Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Gastroenterology Department, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain.
Gastroenterol Hepatol. 2022 Dec;45(10):737-741. doi: 10.1016/j.gastrohep.2021.08.004. Epub 2021 Aug 25.
Several vaccines against SARS-CoV-2 are currently in use and are recommended in inflammatory bowel disease (IBD) patients. Data are scarce about the gastroenterologists and IBD patient's acceptance of SARS-CoV-2 vaccines. The aim of the study was to evaluate the intention to get vaccination with SARS-CoV-2 vaccine among IBD patients from gastroenterologists and patient's perspective.
An online anonymous survey was sent to 8000 patients from ACCU-Spain and 1000 members of the GETECCU. Three invitations were sent between October-December 2020. Descriptive analyses were performed, comparing physicians and patients responses by standard statistical analyses.
144 gastroenterologists [63% female, mean age 43 years (SD 9.5)], and 1302 patients [72% female, mean age 43 years (SD 12)] responded to the survey. 95% of the physicians recommended SARS-CoV-2 vaccine for IBD patients and 87% consider that their vaccination strategies has not changed after the pandemic compared to 12% who considered that they currently refer more patients to vaccination. Regarding to IBD patients, only 43% of patients were willing to receive the vaccine and 43% were not sure. Male sex (p<0.001) and mesalazine treatment (p=0.021) were positively associated with SARS-CoV-2 vaccine acceptance. After multivariate analysis, only male sex was significantly associated with vaccination intent (OR=1.6; 95% confidence interval=1.2-2.0; p=0.001).
Gastroenterologists and patient's perspective about SARS-CoV-2 are different. Future efforts to increase COVID-19 vaccine and decrease unfounded beliefs among IBD patients are needed.
目前有几种针对 SARS-CoV-2 的疫苗正在使用，并被推荐用于炎症性肠病（IBD）患者。关于胃肠病学家和 IBD 患者对 SARS-CoV-2 疫苗的接受程度的数据很少。本研究旨在评估胃肠病学家和患者对 IBD 患者接种 SARS-CoV-2 疫苗的意愿。
我们向 ACCU-Spain 的 8000 名患者和 GETECCU 的 1000 名成员发送了一份在线匿名调查。2020 年 10 月至 12 月期间发送了三封邀请信。通过标准统计分析比较了医生和患者的回答，进行描述性分析。
共有 144 名胃肠病学家[63%为女性，平均年龄 43 岁（SD 9.5）]和 1302 名患者[72%为女性，平均年龄 43 岁（SD 12）]回答了调查。95%的医生建议 IBD 患者接种 SARS-CoV-2 疫苗，87%的医生认为与大流行前相比，他们的疫苗接种策略没有改变，而 12%的医生认为他们目前更倾向于推荐患者接种疫苗。对于 IBD 患者，只有 43%的患者愿意接种疫苗，43%的患者不确定。男性（p<0.001）和接受美沙拉嗪治疗（p=0.021）与 SARS-CoV-2 疫苗接种意愿呈正相关。多变量分析后，只有男性与接种意向显著相关（OR=1.6；95%置信区间 1.2-2.0；p=0.001）。
胃肠病学家和患者对 SARS-CoV-2 的看法不同。需要进一步努力提高 COVID-19 疫苗的接种率，并减少 IBD 患者中毫无根据的信念。
